| Arbyn, M., Ronco, G., Cuzick, J., Wentzensen, N., & Castle, P. E. How to evaluate emerging technologies in cervical cancer screening?, Int J Cancer, vol. 125, no. 11, pp. 2489-2496. |
| Arbyn, M. & Cuzick, J. International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention, Cancer Lett, vol. 278, no. 1, pp. 1-2. |
| Berney, D. M., Gopalan, A., Kudahetti, S., Fisher, G., Ambroisine, L., Foster, C. S., Reuter, V., Eastham, J., Moller, H., Kattan, M. W., Gerald, W., Cooper, C., Scardino, P., & Cuzick, J. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study, Br.J.Cancer, vol. 100, no. 6, pp. 888-893. |
| Bray, F. & Parkin, D. M. Evaluation of data quality in the cancer registry: principles and methods. Part I: Comparability, validity and timeliness, Eur.J Cancer, vol. 45, no. 5, pp. 747-755. |
| Cafferty, F. H., Sasieni, P. D., & Duffy, S. W. A deterministic model for estimating the reduction in colorectal cancer incidence due to endoscopic surveillance, Statistical Methods in Medical Research, vol. 18, no. 2, pp. 163-182. |
| Chang, Y. M., Newton-Bishop, J. A., Bishop, D. T., Armstrong, B. K., Bataille, V., Bergman, W., Berwick, M., Bracci, P. M., Elwood, J. M., Ernstoff, M. S., Green, A. C., Gruis, N. A., Holly, E. A., Ingvar, C., Kanetsky, P. A., Karagas, M. R., Le Marchand, L., Mackie, R. M., Olsson, H., Osterlind, A., Rebbeck, T. R., Reich, K., Sasieni, P., Siskind, V., Swerdlow, A. I., Titus-Ernstoff, L., Zens, M. S., Ziegler, A., & Barrett, J. H. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes, International Journal of Cancer, vol. 124, no. 2, pp. 420-428. |
| Chang, Y. M., Barrett, J. H., Bishop, D. T., Armstrong, B. K., Bataille, V., Bergman, W., Berwick, M., Bracci, P. M., Elwood, J. M., Ernstoff, M. S., Gallagher, R. P., Green, A. C., Gruis, N. A., Holly, E. A., Ingvar, C., Kanetsky, P. A., Karagas, M. R., Lee, T. K., Le Marchand, L., Mackie, R. M., Olsson, H., +ÿsterlind, A., Rebbeck, T. R., Sasieni, P., Siskind, V., Swerdlow, A. J., Titus-Ernstoff, L., Zens, M. S., & Newton-Bishop, J. A. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls, Int J Epidemiol, vol. 38, no. 3, pp. 814-830. |
| Chlebowski, R., Cuzick, J., Amakye, D., Bauerfeind, I., Buzdar, A., Chia, S., Cutuli, B., Linforth, R., Maass, N., Noguchi, S., Robidoux, A., Verma, S., & Hadji, P. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer, Breast, vol. 18 Suppl 2, pp. S1-11. |
| Cummings, S. R., Tice, J. A., Bauer, S., Browner, W. S., Cuzick, J., Ziv, E., Vogel, V., Shepherd, J., Vachon, C., Smith-Bindman, R., & Kerlikowske, K. Prevention of breast cancer in postmenopausal women: Approaches to estimating and reducing risk, Journal of the National Cancer Institute, vol. 101, no. 6, pp. 384-398. |
| Cuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens, F., Senn, H. J., & Thun, M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement, Lancet Oncol., vol. 10, no. 5, pp. 501-507. |
| Cuzick, J., Sestak, I., Pinder, S. E., Ellis, I. O., Hackshaw, A., Bundred, N. J., Forbes, J. F., Bishop, H., Fentiman, I. S., & George, W. D. Beneficial effect of Tamoxifen for women with DCIS: Long-term rresults front the UK/ANZ DCIS trial in women with locally excised DCIS, Cancer Research, vol. 69, no. 24, p. 493S. |
| Cuzick, J., Dowsett, M., Wale, C., Salter, J., Quinn, E., Zabaglo, L., Howell, A., Buzdar, A., & Forbes, J. F. "Prognostic value of a combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and comparison with the GHI Recurrence Score - Results from TransATAC", 24 edn, AMER ASSOC CANCER RESEARCH, San Antonio, TX, p. 503S. |
| Cuzick, J. "Use of selective estrogen receptor modulators in the prevention of breast cancer: An overview of the randomized trials", 24 edn, AMER ASSOC CANCER RESEARCH, San Antonio, TX, p. 532S. |
| Cuzick, J. Orchids of Highland Papua New Guinea, Orchid Society of Great Britain, vol. 58, no. 4, pp. 241-247. |
| Dawson, S. J., Duffy, S. W., Blows, F. M., Driver, K. E., Provenzano, E., LeQuesne, J., Greenberg, D. C., Pharoah, P., Caldas, C., & Wishart, G. C. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival, BRIT J CANCER, vol. 101, no. 8, pp. 1338-1344. |
| Dowsett, M., Cuzick, J., Wales, C., Forbes, J., Mallon, L., Salter, J., Quinn, E., Bugarini, R., Baehner, F. L., Shak, S., & ATAC, T. G. "Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study", 2 edn, AMER ASSOC CANCER RESEARCH, San Antonio, TX, pp. 75S-76S. |
| Duffy, S. R., Distler, W., Howell, A., Cuzick, J., & Baum, M. A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial., Am J Obstet Gynecol., vol. 200, no. 1, p. 80.e1-7. |
| Duffy, S. W. & Treasure, F. P. Potential surrogate endpoints in cancer research - Some considerations and examples, Pharm.Stat.. |
| Duffy, S. W., Raji, O. Y., Agbaje, O. F., Allgood, P. C., Cassidy, A., & Field, J. K. Use of lung cancer risk models in planning research and service programs in CT screening for lung cancer, Expert.Rev.Anticancer Ther., vol. 9, no. 10, pp. 1467-1472. |
| Duffy, S. W. Cost of a 5-year lung cancer survivor, Br.J.Cancer, vol. 101, no. 6, p. 881. |
| Duffy, S. W., Lynge, E., & Jonsson, H. Reply: Estimation of lead-time and overdiagnosis in breast cancer screening, BRIT J CANCER, vol. 100, no. 1, p. 220. |
| Duffy, S. W. The cost of a five-year survivor: Editorial commentary, Br J Cancer, vol. 101, p. 881. |
| Duffy, SW. Commentary on 'What is the point? Will mammographic screening save my life?', BMC Medical Informatics and Decision Making, vol. 9, p. 19. |
| Foster, C. S., Dodson, A. R., Ambroisine, L., Fisher, G., Møller, H., Clark, J., Attard, G., De Bono, J., Scardino, P., Reuter, V. E., Cooper, C. S., Berney, D. M., & Cuzick, J. Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement, Br J Cancer, vol. 101, no. 7, pp. 1137-1144. |
| Fox, A. T., Sasieni, P., du Toit, G., Syed, H., & Lack, G. Reply, J Allergy Clin Immunol, vol. 124, no. 2, pp. 387-388. |
| Fox, A. T., Sasieni, P., du Toit, G., Syed, H., & Lack, G. Household peanut consumption as a risk factor for the development of peanut allergy, J Allergy Clin Immunol, vol. 123, no. 2, pp. 417-423. |
| Franceschi, S., Cuzick, J., Herrero, R., Dillner, J., & Wheeler, C. M. EUROGIN 2008 roadmap on cervical cancer prevention, Int J Cancer, vol. 125, no. 10, pp. 2246-2255. |
| Gillan, M. G. C., Gilbert, F. J., Flight, H., Cooper, J., Wallis, M. G., James, J. J., Boggis, C. R. M., Astley, S. M., Agbaje, O. F., & Duffy, S. W. Increasing participant recruitment into large-scale screening trials: experience from the CADET II study, J.Med.Screen., vol. 16, no. 4, pp. 180-185. |
| Harvie, M., Chapman, M., Cuzick, J., Flyvbjerg, A., Jebb, S., Mattson, M., & Howell, A. "The effect of intermittent versus continuous energy restriction on biomarkers of breast cancer", 2 edn, AMER ASSOC CANCER RESEARCH, San Antonio, TX, pp. 95S-96S. |
| Holmberg, L., Duffy, S. W., Yen, A. M. F., Tabar, L., Vitak, B., Nystrom, L., & Frisell, J. Differences in endpoints between the Swedish W-E (two county) trial of mammographic screening and the Swedish overview: Methodological consequences, J Med Screen, vol. 16, no. 2, pp. 73-80. |
| Houssami, N., Ciatto, S., Martinelli, F., Bonardi, R., & Duffy, S. W. Early detection of second breast cancers improves prognosis in breast cancer survivors, Ann.Oncol., vol. 20, no. 9, pp. 1505-1510. |
| Ingle, J. N., Dowsett, M., Cuzick, J., & Davies, C. "Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: Meta-analyses of randomized trials of monotherapy and switching strategies", 2 edn, AMER ASSOC CANCER RESEARCH, San Antonio, TX, p. 66S. |
| Kerkhot, M., Roobol, M. J., Steyerberg, E. W., Cuzick, J., & Schroder, F. H. "Secondary analysis of the European Randomised Study of Screening for Prostate Cancer (ERSPC): Effect of prostate cancer screening on the development of metastases after adjustment for non-compliance and contamination", 4 edn, ELSEVIER SCIENCE INC, Chicago, IL, p. 233. |
| Kitchener, H. C., Almonte, M., Thomson, C., Wheeler, P., Sargent, A., Stoykova, B., Gilham, C., Baysson, H., Roberts, C., Dowie, R., Desai, M., Mather, J., Bailey, A., Turner, A., Moss, S., & Peto, J. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): A randomised controlled trial, Lancet Oncol, vol. 10, no. 7, pp. 672-682. |
| Kitchener, H. C., Almonte, M., Gilham, C., Dowie, R., Stoykova, B., Sargent, A., Roberts, C., Desai, M., & Peto, J. ARTISTIC: A randomised trial of human papillomavirus (HPV) testing in primary cervical screening, Health Technol.Assess., vol. 13, no. 51, p. 1-iv. |
| Kudahetti, S., Fisher, G., Ambroisine, L., Foster, C., Reuter, V., Eastham, J., Møller, H., Kattan, M. W., Cooper, C. S., Scardino, P., Cuzick, J., & Berney, D. M. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer., BJU Int.. |
| Lace, M. J., Isacson, C., Anson, J. R., Lorincz, A. T., Wilczynski, S. P., Haugen, T. H., & Turek, L. P. Upstream regulatory region alterations found in Human Papillomavirus Type 16 (HPV-16) isolates from cervical carcinomas increase transcription, ori function, and HPV immortalization capacity in culture, J VIROL, vol. 83, no. 15, pp. 7457-7466. |
| Larsen, I. K., Smastuen, M., Johannesen, T. B., Langmark, F., Parkin, D. M., Bray, F., & Moller, B. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness, Eur.J Cancer, vol. 45, no. 7, pp. 1218-1231. |
| Lawrence, G., Wallis, M., Allgood, P., Nagtegaal, I. D., Warwick, J., Cafferty, F. H., Houssami, N., Kearins, O., Tappenden, N., O'Sullivan, E., & Duffy, S. W. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias, Breast Cancer Res.Treat., vol. 116, no. 1, pp. 179-185. |
| Le, H. V., Schoenbach, V. J., Herrero, R., Hoang Pham, A. T., Nguyen, H. T., Nguyen, T. T., Munoz, N., Franceschi, S., Vaccarella, S., Parkin, M. D., Snijders, P. J., Morrow, R. A., & Smith, J. S. Herpes simplex virus type-2 seropositivity among ever married women in South and north Vietnam: A population-based study, Sex Transm.Dis., vol. 36, no. 10, pp. 616-620. |
| Lorincz, A. T. Opinion Leaders Roundtable - Vaccines for Human Papillomavirus, Arch Med de Actual Tracto Gen Inf, vol. 1, pp. 18-20. |
| Oliver, T., Lorincz, A., & Cuzick, J. Prostate cancer prevention by short-term anti-androgens: The rationale behind design of pilot studies, Recent Results Cancer Res., vol. 181, pp. 195-205. |
| Paovonen, J., Naud, P., Salmeron, J., Wheeler, C. M., Chow, S. N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J. C., Skinner, S. R., Hedrick, J., Jaisamrarn, U., Limson, G., Garland, S., Szarewski, A., Romanowski, B., Aoki, F. Y., Schwarz, T. F., Poppe, W. A. J., Bosch, F. X., Jenkins, D., Hardt, K., Zahaf, T., Descamps, D., Struyf, F., Lehtinen, M., & Dubin, G. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women, Lancet, vol. 374, no. 9686, pp. 301-314. |
| Parkin, D. M., Olsen, A. H., & Sasieni, P. The potential for prevention of colorectal cancer in the UK, Eur.J.Cancer Prev., vol. 18, no. 3, pp. 179-190. |
| Parkin, D. M. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?, Eur.J.Cancer, vol. 45, no. 9, pp. 1649-1653. |
| Parkin, D. M. & Bray, F. Evaluation of data quality in the cancer registry: Principles and methods Part II. Completeness, Eur.J Cancer, vol. 45, no. 5, pp. 756-764. |
| Pashayan, N., Duffy, S. W., Pharoah, P., Greenberg, D., Donovan, J., Martin, R. M., Hamdy, F., & Neal, D. E. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: Implications of sojourn time on screening, British Journal of Cancer, vol. 100, no. 7, pp. 1198-1204. |
| Pashayan, N., Pharoah, P., Neal, D. E., Hamdy, F., Donovan, J., Martin, R. M., Greenberg, D., & Duffy, S. W. Stage shift in PSA-detected prostate cancers - Effect modification by Gleason score, J.Med.Screen., vol. 16, no. 2, pp. 98-101. |
| Perrett, C. M., Harwood, C. A., McGregor, J. M., Warwick, J., Cerio, R., & Karran, P. Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients, Br.J.Dermatol.. |
| Rajab, R., Fisher, G., Ambroisine, L., Foster, C. S., Moller, H., Kattan, M., Reuter, V., Scardino, P., Cuzick, J., & Berney, D. M. "The predictive power of prostate cancer Extent measurements in a large watchful waiting cohort", NATURE PUBLISHING GROUP, Boston, MA, p. 190A. |
| Raji, O. Y., Agbaje, O. F., Duffy, S. W., & Field, J. K. The predictive ability of LLP lung cancer risk model with and without seizure 6-Like (SEZ6L) gene, J THORAC ONCOL, vol. 4, no. 9, p. S408-S409. |
| Robles, S. C., Ferreccio, C., Tsu, V., Winkler, J., Almonte, M., Bingham, A., Lewis, M., & Sasieni, P. Assessing participation of women in a cervical cancer screening program in Peru, Rev.Panam.Salud Publica, vol. 25, no. 3, pp. 189-195. |
| Roobol, M. J., Kerkhof, M., Schroder, F. H., Cuzick, J., Sasieni, P., Hakama, M., Stenman, U. H., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L., Recker, F., Berenguer, A., Ruutu, M., Kujala, P., Bangma, C. H., Aus, G., Tammela, T. L., Villers, A., Rebillard, X., Moss, S. M., de Koning, H. J., Hugosson, J., & Auvinen, A. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC), Eur.Urol., vol. 56, no. 4, pp. 584-591. |
| Sasieni, P., Castanon, A., & Parkin, D. M. How many cervical cancers are prevented by treatment of screen-detected disease in young women?, International Journal of Cancer, vol. 124, no. 2, pp. 461-464. |
| Sasieni, P., Castle, P. E., & Cuzick, J. Further analysis of the ARTISTIC trial, Lancet Oncol., vol. 10, no. 9, pp. 841-842. |
| Sasieni, P., Castanon, A., & Cuzick, J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data, BMJ, vol. 339, p. b2968. |
| Sasieni, P., Castanon, A., & Cuzick, J. Screening and adenocarcinoma of the cervix, Int J Cancer, vol. 125, no. 3, pp. 525-529. |
| Satitvipawee, P., Promthet, S. S., Pitiphat, W., Kalampakorn, S., & Parkin, D. M. Factors associated with breast self-examination among Thai women living in rural areas in Northeastern Thailand, J Med Assoc.Thai., vol. 92 Suppl 7, p. S29-S35. |
| Sestak, I., Sapunar, F., & Cuzick, J. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial, J.Clin.Oncol., vol. 27, no. 30, pp. 4961-4965. |
| Stankiewicz, E., Kudahetti, S. C., Prowse, D. M., Ktori, E., Cuzick, J., Ambroisine, L., Zhang, X., Watkin, N., Corbishley, C., & Berney, D. M. HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis, Mod.Pathol., vol. 22, no. 9, pp. 1160-1168. |
| Stone, J., Warren, R. M., Pinney, E., Warwick, J., & Cuzick, J. Determinants of percentage and area measures of mammographic density, Am.J.Epidemiol., vol. 170, no. 12, pp. 1571-1578. |
| Syrjänen, K., Shabalova, I., Naud, P., Kozachenko, V., Derchain, S., Zakharchenko, S., Roteli-Martins, C., Nerovjna, R., Longatto, A., Kljukina, L., Tatti, S., Branovskaja, M., Hammes, L. S., Branca, M., Grunjberga, V., Erzen, M., Sarian, L. O., Juschenko, A., Costa, S., Podistov, J., & Syrjanen, S. Persistent high-risk Human Papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the new independent states of the Former Soviet Union and the Latin American screening study cohorts, International Journal of Gynecological Cancer, vol. 19, no. 5, pp. 934-942. |
| Szarewski, A. Sisters doing it for themselves., J Fam Plann Reprod Health Care, vol. 35, no. 2, pp. 71-72. |
| Szarewski, A., Cadman, L., Ashdown-Barr, L., & Waller, J. Exploring the acceptability of two self-sampling devices for human papillomavirus testing in the cervical screening context: a qualitative study of Muslim women in London, J.Med.Screen., vol. 16, no. 4, pp. 193-198. |
| Szarewski, A. Raising awareness of human papillomavirus and cervical cancer prevention: The need for clinical education, Future Virology, vol. 4, no. 5, pp. 431-436. |
| Szarewski, A. Choice of contraception, Obstet Gynaecol & Reproduct Med, vol. 19, pp. 323-326. |
| Szarewski, A. Prophylactic HPV vaccines, The NHS Trust Association, London. |
| Szymanska, K., Chen, J. G., Cui, Y., Gong, Y. Y., Turner, P. C., Villar, S., Wild, C. P., Parkin, D. M., & Hainaut, P. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China, Cancer Epidemiol.Biomarkers Prev., vol. 18, no. 5, pp. 1638-1643. |
| Visvanathan K, Lippman SM, Hurley P, & Temin S. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction., Gynecol Oncol, vol. 115, no. 1, pp. 132-134. |
| Visvanathan, K., Chlebowski, R. T., Hurley, P., Col, N. F., Ropka, M., Collyar, D., Morrow, M., Runowicz, C., Pritchard, K. I., Hagerty, K., Arun, B., Garber, J., Vogel, V. G., Wade, J. L., Brown, P., Cuzick, J., Kramer, B. S., Lippman, S. M., & American Society of Clinical Oncology. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including Tamoxifen, Raloxifene, and Aromatase Inhibition for breast cancer risk reduction, J Clin Oncol, vol. 27, no. 19, pp. 3235-3258. |
| Wald, N. J., Law, M. R., & Duffy, S. W. Breast screening saves lives, BMJ, vol. 339, p. b2922. |
| Warwick, J., Vardaki, E., Fattizzi, N., McNeish, I., Jeyarajah, A., Oram, D., Hassan, L., Covens, A., Duffy, S., & Reynolds, K. Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategies, BJOG., vol. 116, no. 9, pp. 1225-1241. |
| Whitlock, G., Lewington, S., Sherliker, P., Clarke, R., Emberson, J., Halsey, J., Qizilbash, N., Collins, R., Peto, R., Lewington, S., MacMahon, S., Peto, R., Aromaa, A., Baigent, C., Carstensen, J., Chen, Z., Clarke, R., Collins, R., Duffy, S., Kromhout, D., Neaton, J., Qizilbash, N., Rodgers, A., Tominaga, S., Tornberg, S., Tunstall-Pedoe, H., Whitlock, G., Chambless, L., De Backer, G., De Bacquer, D., Kornitzer, M., Whincup, P., Wannamethee, S. G., Morris, R., Wald, N., Morris, J., Law, M., Knuiman, M., Bartholomew, H., Smith, G. D., Sweetnam, P., Elwood, P., Yarnell, J., Kronmal, R., Kromhout, D., Sutherland, S., Keil, J., Jensen, G., Schnohr, P., Hames, C., Tyroler, A., Aromaa, A., Knekt, P., Reunanen, A., Tuomilehto, J., Jousilahti, P., VArtiainen, E., Puska, P., Kuznetsova, T., Richart, T., Staessen, J., Thijs, L., Jorgensen, T., Thomsen, T., Sharp, D., Curb, J. D., Qizilbash, N., Iso, H., Sato, S., Kitamura, A., Naito, Y., Benetos, A., Guize, L., Goldbourt, U., Tomita, M., Nishimoto, Y., Murayama, T., Criqui, M., Davis, C., Hart, C., Smith, G. D., Hole, D., Gillis, C., Jacobs, D., Blackburn, H., Luepker, R., Neaton, J., Eberly, L., Cox, C., Levy, D., D'Agostino, R., Silbershatz, H., Tverdal, A., Selmer, R., Meade, T., Garrow, K., Cooper, J., Speizer, F., Stampfer, M., Menotti, A., Spagnolo, A., Tsuji, I., Imai, Y., Ohkubo, T., Hisamichi, S., Haheim, L., Holme, I., Hjermann, I., Leren, P., Ducimetiere, P., Empana, J., Jamrozik, K., Broadhurst, R., Assmann, G., Schulte, H., Bengtsson, C., Bjorkelund, C., Lissner, L., Sorlie, P., Garcia-Palmieri, M., Barrett-Conner, E., Criqui, M., Langer, R., Hart, C., Smith, G. D., Hole, D., Nakachi, K., Imai, K., Fang, X., Li, S., Buzina, R., Nissinen, A., Aravanis, C., Dontas, A., Kafatos, A., Menotti, A., Adachi, H., Toshima, H., Imaizumi, T., Kromhout, D., Nedeljkovic, S., Ostojic, M., Chen, Z., Tunstall-Pedoe, H., Nakayama, T., Yoshiike, N., Yokoyama, T., Date, C., Tanaka, H., Keller, J., Bonaa, K., Arnesen, E., Tunstall-Pedoe, H., Rimm, E., Gaziano, M., Buring, J. E., Hennekens, C., Tornberg, S., Carstensen, J., Shipley, M., Leon, D., Marmot, M., Clarke, R., Collins, R., Emberson, J., Halsey, J., Lewington, S., Palmer, A., Parish, S., Peto, R., Sherliker, P., & Whitlock, G. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies, Lancet, vol. 373, no. 9669, pp. 1083-1096. |
|
